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SDZ RAD [40-O-(2-hydroxyethyl)rapamycin] is a macrolide immunosuppressant that is
currently under clinical investigation after organ transplantation. The elucidation of its
metabolic pathway is essential to improve the understanding of its therapeutic potentials and
safety. In this article we describe investigations on the structural identification of some major
metabolites of the drug produced by human liver microsomes in vitro. The principles
described may be generally applicable for the structural elucidation of complex compound
mixtures in biological matrices. Under the conditions of electron impact ionization, SDZ RAD
undergoes extensive fragmentation and no information sufficient for structural elucidation is
obtained. Therefore, mass spectrometry based on soft electrospray ionization (ESI) in conjunc-
tion with collision-induced fragmentation was the method of choice. High-performance liquid
chromatography coupled to an ESI mass spectrometer resulted in separation and identification
of 16-O-demethyl-SDZ RAD, the ring-opened form of SDZ RAD, and its dehydrate. Addition-
ally, we characterized several demethylated and hydroxylated metabolites. (J Am Soc Mass
Spectrom 1998, 9, 1267–1274) © 1998 American Society for Mass Spectrometry
Drugs of the macrolide class are of widespreaduse in modern antimicrobial and immunosup-pressive therapy [1–5]. Tacrolimus (FK-506, Fu-
jisawa, Osaka, Japan) and sirolimus (rapamycin,
Wyeth-Ayerst, Princeton, NJ) represent a generation of
highly potent macrolide immunosuppressants that en-
tered the market lately or are under development.
Clinical investigation of SDZ RAD [40-O-(2-hydroxy-
ethyl)rapamycin, Novartis Pharma, Basel, Switzerland,
Figure 1], another structurally related compound based
on a 31-membered macrolide lactone, has recently en-
tered the stage of clinical investigation. The molecular
formula is C53H83NO14, giving a molecular weight of
957.58 Da. Its application in combination with ciclos-
porin represents a new therapeutic approach that could
open new therapeutic regimens in immunosuppressive
therapy.
An automated method for therapeutic drug monitor-
ing of SDZ RAD has already been provided by means of
electrospray ionization-mass spectrometry (ESI-MS)
and allows sensitive and specific measurement of the
drug in blood. The metabolism of the drug is still
awaiting elucidation that would allow a better under-
standing of the role of its metabolites in therapeutic
efficacy and on possible side effects.
ESI-MS as a gentle ionization technique applicable to
compounds not accessible by electron impact ionization
has been used for detection and quantitation of many
drugs [7–9]. Chromatographic separation of heat sensi-
tive and highly polar compounds prior to ESI-MS
measurement can be carried out on-line [10]. ESI-MS is
already well established for routine analytical problems
outperforming other methods in sensitivity and speci-
ficity. Structural elucidation by ESI-MS is an application
field of growing importance. Numerous applications
are described in the literature, including the identifica-
tion of metabolites and biological compounds—both in
vivo and in vitro [11–18].
In this paper data are presented on the metabolic
pathway of SDZ RAD after in vitro incubation with
human liver microsomes. Because SDZ RAD under the
conditions of electron impact ionization undergoes ex-
tensive fragmentation with insufficient structural infor-
mation (C. Vidal and G. Scheeder, unpublished), mass
spectrometry based on soft ESI in conjunction with
collision-induced fragmentation was the method of
choice. The technique described may be generally ap-
plicable for the structural elucidation of complex com-
pound mixtures in biological matrices using high-per-
formance liquid chromatography (HPLC) coupled to
ESI-MS. Guided by the fragmentation schemes of trans-
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formation products identified during LC/MS under the
conditions of ESI in conjunction with collision-induced
dissociation (CID), the capabilities and limitations of
structural elucidation by ESI-MS are discussed.
Experimental
Materials
Acetonitrile, methanol, and water were of gradient
grade and provided by J. T. Baker, Deventer, Nether-
lands. Ammonium acetate (.99%) was obtained from
Fluka, Neu-Ulm, Germany. SDZ RAD was kindly pro-
vided by Novartis Pharma, Basel, Switzerland. Human
liver microsomes were isolated according to a method
published elsewhere [18] from hepatic tissue provided
after liver resection. Microsomes from three individuals
(two females, one male) were pooled for this study. A
pH 7.4 phosphate buffer solution was prepared from
Na2HPO4 and NaH2PO4 (Sigma Aldrich, Deisenhofen,
Germany) and an NADPH generating system was used
[2 mmol/L ethylenediaminetetraacetic acid (EDTA), 10
mmol/L MgCl2, 0.84 mmol/L NADP, 18 mmol/L iso-
citric acid]. Nitrogen (99.999%) for the mass spectromet-
ric system was obtained from Linde AG, Ho¨llriegels-
kreuth, Germany.
Instrumentation
Compounds were separated on an HP series 1100 liquid
chromatograph (Hewlett-Packard, Waldbronn, Ger-
many) equipped with a G 1322 A vacuum degasser, a G
1312 A binary pump, a G 1313 A autosampler, and a G
1316 A column thermostat. The HPLC system was
controlled by the HP ChemStation for LC software
(Rev. A.04.01) run on an IBM compatible PC with an
HP-IB interface.
The HPLC system was coupled to a Finnigan MAT
95 S high resolution mass spectrometer equipped with
an API electrospray interface (Finnigan MAT, Bremen,
Germany). A Harvard Apparatus 22 syringe pump
(Harvard Apparatus, South Natick, MA) and a Hamil-
ton 2.5 mL syringe were used to provide sheath flow.
Device control and data acquisition were achieved with
the ICIS software (Rev. 10.2) run on a UNIX worksta-
tion.
Mass Spectrometry
After separation of the analytes on the analytical col-
umn the compounds were injected into the electrospray
interface with pneumatic assistance from a flow of
nitrogen at 600 kPa. The capillary of the API interface
was heated to 300°C, needle voltage was 3.5 kV. A
sheath flow of 15 mL/min (90% acetonitrile/10% am-
monium acetate solution 5 mmol/L) was provided by a
syringe pump. All mass spectrometric measurements
were made in the positive ion mode. The mass analyzer
was set to detect mass-to-charge ratios between 300 and
1100, scan time was 20 s/decade, mass resolution was
R 5 1500.
Methods
Sample preparation. For incubation with human liver
microsomes, 650 mL phosphate buffer pH 7.4 were
added to 300 mL of the NADPH generating system and
50 mL microsome suspension (3 g/L protein). The
mixture was spiked with 10 mg in 1 mL SDZ RAD and
incubated in a water bath at 37°C for 60 min. After
protein precipitation with 500 mL acetonitrile, the sam-
ples were centrifuged for 5 min at 8500 rpm. The
supernatant was extracted on C 18 solid phase extrac-
tion columns (Clin Rep, Merck, Darmstadt, Germany)
activated with 2 mL water. After elution with 1.6 mL
acetonitrile, the eluates of ten samples were pooled and
the solvent was evaporated under a flow of nitrogen to
give a volume of 0.3 mL, which was transferred to an
autosampler vial with 350 mL insert for LC/MS mea-
surement.
A control sample without addition of SDZ RAD, one
sample with SDZ RAD but without microsomes and a
standard solution of the drug dissolved in acetonitrile
were identically incubated, prepared, and measured.
LC/MS measurements. The compounds were separated
using a 100 3 2.1 mm Hypersil ODS column (particle
size 3 mm) equipped with a 20 3 2.1 mm guard column
filled with identical material (Hewlett-Packard, Wald-
bronn, Germany) at a flow of 0.2 mL/min and gradient
elution. Mobile phase component A was water and
component B was methanol. The following gradient
was used: 0 min, 60% (v/v) B; 25–42 min, 70% (v/v) B,
50–70 min, 80% (v/v) B. Injection volume was set to 40
mL, the column was heated to 30°C. After each chro-
matographic run, the analytical column was recondi-
tioned by a flow of 0.2 mL/min methanol for 5 min and
it was subsequently re-equilibrated to 60% methanol/
40% water for 20 min.
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Each sample had to undergo two LC/MS runs, one
without CID in the skimmer region of the API interface,
one with application of a CID voltage adjusted to a
value to give half the intensity for the parent compound
SDZ RAD.
Results and Discussion
In the LC/MS chromatograms of the microsomal ex-
tracts several peaks were detected representing metab-
olites and transformation products of SDZ RAD mainly
as the sodium adduct ions [M1Na]1. The potassium
adduct ions [M1K]1 of the compounds gave signals of
low intensity (,5% of the analogous [M1Na]1) and
had the same retention times as the respective sodium
adduct ions. They were not considered for further
interpretation and identification purposes.
In a first step, LC/MS runs were recorded without
application of CID to determine the (quasi) molecular
ions of the compounds present in the samples. Figure 2
depicts LC/MS chromatograms recorded from extracts
under different incubation conditions. Table 1 summa-
rizes the mass-to-charge ratio values of the predomi-
nant ion signals obtained from the chromatographic
peaks at the retention times tR given in brackets and
used for structural identification. The information from
Table 1 was taken as a basis for the identification of the
signals as the (quasi) molecular ions of transformation
products. An LC/ESI-MS chromatogram of SDZ RAD
after 60 min of incubation with human liver micro-
somes recorded without application of CID is shown in
Figure 2d). Only signals exclusively appearing in this
chromatogram were considered for further identifica-
tion of metabolites. Apart from the parent compound
(tR 5 53.1 min) the most intense peaks have to be
attributed to m/z 996.5, representing at least five hy-
droxylated forms of the parent compound, and to m/z
966.5, representing a demethylated metabolite.
LC/MS runs with application of CID delivered spec-
tra containing fragments of the respective compounds.
The in-source CID spectrum recorded at tR 5 53.1 min
(Figure 3d) proved to be attributable to the parent
compound. Based on the spectral data, fragments cor-
responding to the major signals obtained could be
tentatively identified. In this way, it was possible to
compose a fragmentation scheme for SDZ RAD which
is depicted in Figure 4 and which is the basis of all
further structural interpretations.
Although we did not achieve chromatographic base-
line resolution in all cases, spectral data allowed struc-
tural identification of three compounds (see Figure 5)
and encircling of the transformation positions of some
Figure 2. LC/ESI-MS chromatograms of extracts from incubates for 60 min at 37°C under different
conditions: (a) incubation buffer with microsomes without SDZ RAD, (b) standard solution of SDZ
RAD in acetonitrile, (c) SDZ RAD in incubation buffer without microsomes, and (d) incubation of SDZ
RAD with human liver microsomes. All data were recorded without application of CID: shown is the
total ion current of a run in scan mode (m/z 300–1100); the intensity is given in arbitrary units for each
run. Arrows in (d) indicate signals used for structural identification.
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other metabolites. Further species coeluted with other
compounds or they were obtained with lower intensity,
so that they were not considered for structural elucida-
tion. In all samples spiked with SDZ RAD a further
signal was obtained at tR 5 57.5 min (see Table 1) with
an m/z of 980.5 which is known to be a tautomer of the
parent drug (C. Hauck, personal communication). The
fragmentation pattern was very similar to that obtained
for the parent compound, but it was not further identi-
fied.
Figure 3 depicts the obtained in-source CID spectra
for SDZ RAD and its identified transformation products
recorded at retention times of tR 5 5.1 min (a), 8.5 min
(b), 31.0 min (c), and 53.1 min (d). As described below,
Table 1. Overview of the incubation experiments and the obtained LC/MS data recorded without application of CID: the table
shows the mass-to-charge ratio values and in parentheses retention times tR of the predominant signals obtained during
chromatographic separation used for structural identification. All samples were incubated for 60 min at 37°C
Sample SDZ RAD Microsomes m/z values and retention times of signals
Standard solution of SDZ RAD in acetonitrile yes no m/z 980.5 (tR 5 53.1 min, 57.5 min)
Incubation buffer with microsomes without
SDZ RAD
no yes no signals observed
SDZ RAD in incubation buffer without
microsomes
yes no m/z 980.5 (tR 5 53.1 min, 57.5 min)
SDZ RAD incubated with microsomes yes yes m/z 966.5 (tR 5 31.0 min)
m/z 980.5 (tR 5 53.1 min, 57.5 min)
m/z 996.5 (tR 5 24.0 min, 30.0 min, 32.4
min, 35.1 min, 41.1 min)
m/z 1002.5 (tR 5 8.5 min)
m/z 1004.5 (tR 5 11.0 min)
m/z 1012.5 (tR 5 12.4 min, 19.4 min)
m/z 1020.5 (tR 5 5.1 min)
Figure 3. In-source CID spectra of (a) the ring-opened form of SDZ RAD (tR 5 5.1 min), (b) the
dehydrate of the ring-opened form of SDZ RAD (tR 5 8.5 min), (c) 16-O-demethyl-SDZ RAD
(tR 5 31.0 min), and (d) SDZ RAD (tR 5 53.1 min) acquired during LC/ESI-MS.
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Figure 4. Proposal of the fragmentation scheme of SDZ RAD derived from the ESI-CID spectrum
(Figure 3d); shown are the basic fragments relevant for structural elucidation of the metabolites,
numbered in clockwise order around the page.
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the compounds could be identified as the ring-opened
form of SDZ RAD (a), the dehydrate of the ring-opened
form of SDZ RAD (b), 16-O-demethyl-SDZ RAD (c),
and the parent compound (d).
The Ring-Opened Form of SDZ RAD
In the CID spectrum of the metabolite eluting at
tR 5 5.1 min (Figure 3a) the most prominent signals are
those with m/z 389, 407, 429, 636, 998, and 1020. This
indicates a metabolite with a molecular ion of 998 Da
which underwent opening of the macrolide ring struc-
ture and to which a water molecule was added. The
position in the parent compound most susceptible for
such a transformation is the lactone function. The
signals obtained underline this structural proposal:
m/z 407 corresponds to fragment IX of the parent
compound (Figure 4) containing an additional water
molecule. Through elimination of water, m/z 389 (frag-
ment IX) is generated under CID conditions. For the
m/z 429 signal, the structure of fragment IX plus water
as a double sodium adduct [fragment 2 H12Na]1 or
fragment XII is possible. In the case of m/z 636, there
are good arguments in favor of a double sodium adduct
[fragment 2 H12Na]1 for fragment V (Figure 4) con-
taining a carboxylic acid function (see discussion, and
[19]). No fragments were found corresponding to struc-
tures with the lactone ring conserved. In conclusion, the
predominance of ring-opened fragments without mass
shifts in comparison to the basic fragments of SDZ
RAD, the lack of fragments containing ester groups and
fragment IX with a mass shift of 118 Da strongly
suggest the structure of the ring-opened form of SDZ
RAD.
The Dehydrate of the Ring-Opened Form of
SDZ RAD
The metabolite at tR 5 8.5 min showed a CID spectrum
very similar to that of the ring-opened form of SDZ
RAD, with the exception that m/z 1002 was detected as
the highest mass with a shift of 218 Da in comparison
to the ring-opened form of SDZ RAD and that it lacks a
signal at m/z 407 (Figure 3b). As discussed above, m/z
636 corresponds to the proposed fragment V as the
double sodium adduct (122 Da) and indicates that the
drug has not been modified at the carbon chain between
C(1) and C(27). Signals at m/z 389 and 429 were
attributable to the fragments IX and XII of the parent
drug. In conclusion, the spectrum obtained allows iden-
tification of the compound as the dehydrate of the
ring-opened form of SDZ RAD with a resulting mass of
980 Da. Because of the ring-opened structure the mo-
lecular ion is detected as the double sodium adduct
with a mass of 122 Da added to the [M1Na]1.
16-O-Demethyl-SDZ RAD
The compound eluting at tR 5 31.0 min (Figure 3c) was
identified as 16-O-demethyl-SDZ RAD for the follow-
ing reasons: The base peak at m/z 966 was indicative
for the sodium adduct ion of a demethylated product of
SDZ RAD. The main fragments appeared at m/z 320,
389, 409, 453, 471, 518, 582, 651, 837, and 948 and have
the same masses as the respective fragments VIII, IX,
XIII, XIV, XV, X, VI, XI, II, I of the parent compound
(Figure 4). All of these fragments containing C(15) and
C(16) are characterized by a double bond between those
two carbon atoms. The only exception from that is the
signal at m/z 600 corresponding to fragment V of the
parent compound with a mass shift of 214 Da. There-
fore, the only region possible for demethylation is the
methoxy group at C(16).
Figure 5. Proposed structures of the transformation products of
SDZ RAD identified by HPLC/ESI-MS: (a) 16-O-demethyl-SDZ
RAD, (b) the ring-opened form of SDZ RAD, and (c) the dehydrate
of the ring-opened form of SDZ RAD.
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Monohydroxylated Metabolites of SDZ RAD
Five different signals showing a mass shift of 116 Da to
SDZ RAD were obtained and distinctly different CID
spectra were recorded. These compounds, which were
hydroxylated in one position during incubation, can be
divided into two groups: four of them (tR 5 24.0, 30.0,
32.4, and 35.1 min) showed fragments with a mass shift
of 116 Da in comparison with fragments III, V, VI, XIV
of the parent compound and signals corresponding to
fragments X and IX were obtained without mass shift.
The fifth hydroxylated species (tR 5 41.1 min) pro-
duced signals without mass shift in comparison with
those for SDZ RAD referring to fragments V and XIV.
Fragments III, IV, and IX were detected with a mass
shift of 116 Da. This allowed us to conclude that
hydroxylation must have occurred between C(8) and
C(27) producing the four compounds eluting at
tR 5 24.0, 30.0, 32.4, and 35.1 min and in the part of the
molecule containing the carbon chain from C(28) to
C(42) in the case of the fifth monohydroxylated metab-
olite (tR 5 41.1 min).
For the monohydroxylated compound detected at
tR 5 24.0 min, the position of transformation could be
further encircled. Additional signals were detected at
m/z 457 (fragment XIII hydroxylated1CH3OH) and at
m/z 425 indicating loss of methanol. In contrast to the
other hydroxylated compounds of the first group, no
m/z values of 407 and 439 indicating loss of water were
observed. In conclusion, hydroxylation has to be lo-
cated in a position where water and methanol can only
be eliminated alternatively, so that after loss of metha-
nol the elimination of water is blocked. Therefore
hydroxylation must have occurred at C(15), C(16), or
C(44).
Products of Multiple Transformations
Several metabolites multiply modified have been dis-
covered, among them at least two dihydroxylated de-
rivatives (m/z 1012, tR 5 12.4 and 19.4 min, see Table
1) showing the most intense signals with a mass shift of
132 Da in comparison with the parent compound.
Furthermore, the metabolite 39-O-demethyl-hydroxy-
SDZ RAD (tR 5 11.0 min) was identified, where the
hydroxylation position must be located in the part of
the molecule between C(28) and C(54). In contrast to all
other species identified so far, instead of a signal at m/z
389 (fragment IX) one of the predominant signals was
m/z 391, corresponding to fragment IX modified by
subsequent hydroxylation and demethylation. Other
strong signals were detected at m/z 429, 636, and 1004
indicating fragment XII, fragment V as a double sodium
adduct ion, and the double sodium adduct ion of
demethyl-hydroxy-SDZ RAD.
According to this study, SDZ RAD is metabolized by
human liver microsomes to at least 20 compounds. All
compounds identified were exclusively detected in
samples after incubation with microsomes, so that they
can be considered as metabolites and not as degrada-
tion products. Although the ring-opened products are
known to be degradation products (C. Hauck, personal
communication), they seem to be the result of a bio-
transformation because they were only found in incu-
bates containing human liver microsomes. It is concluded
from our study that ring-opening, hydroxylation, de-
methylation, and multiple combinations of them are the
predominant in vitro metabolic pathways of SDZ RAD.
This is completely in line with results obtained by Streit
et al. who investigated the in vitro metabolism of the
structurally related drug sirolimus and who found the
main in vitro transformations to be demethylation and
hydroxylation [19]. The metabolism reported for tacroli-
mus, a further macrolide immunosuppressant similar to
SDZ RAD, is likewise characterized by demethylation
and hydroxylation steps [21]. In line with the findings
for tacrolimus and sirolimus it is likely that demethyl-
ation preferentially occurs at methoxy groups.
The microsomes used were pooled from three indi-
viduals. Because polarity of the transformation prod-
ucts covers a wide range as expressed by distinct
retention times, ionization efficiency during the electro-
spray ionization process may not be assumed to be
equal for all components observed. Therefore, the re-
sults obtained do not allow quantification.
The use of LC separation coupled to mass spectro-
metry for direct structural identification of the com-
pounds eluting from the analytical column proved to be
of practical value. Streit et al. prefractionated their
incubation extracts by semipreparative off-line HPLC
[19]. This technique does not allow distinction between
compounds equal in molecular mass eluting nearly
superimposibly and collected in the same fraction.
The chromatographic conditions chosen resulted in
sufficient resolution of the main metabolic transforma-
tion products and were adequate to allow the acquisi-
tion of CID spectra leading to structural identification.
Regarding to the variety of metabolites equal in molec-
ular mass, adequate LC separation is an essential pre-
requisite even for MS/MS experiments.
Frequently double sodium adduct ions were found
in cases where the proposed structure of the respective
fragment had a carboxylic acid function. Coordination
of a second sodium cation seems to be likely for such a
structural constellation as the acidic function can be
mesomerically stabilized by abstraction of a proton
creating a carboxylate anion, and another sodium ion
can be easily coordinated to that position. In the case of
the molecular ion of the ring-opened form of SDZ RAD
(see above), which appears as the [M 2 H 1 2 Na]1
(m/z 1020) in the spectrum, this phenomenon is clearly
demonstrated.
Our investigations have shown that under the con-
ditions of CID the main pathway of fragmentation is a
cleavage. ESI is a very gentle ionization technique
leading to well-distinguished preferences in the forma-
tion of different alkali adduct ions. Comparing the
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spectra of the ring-opened form of SDZ RAD and its
dehydrate (Figure 3b, c), there are two additional sig-
nals at m/z 445 and 652 in the spectrum of the hydrated
derivative. Both spectra had a signal with a mass shift of
116 Da with regard to the [M 2 H12 Na]1, which in
the case of the hydrated compound is more intensive
than the signal of the double sodium adduct ion with-
out mass shift. Through ring-opening and introduction
of an additional hydroxy function, the affinity for
adduction of potassium as the second alkali ion appears
to be increased, which leads to the formation of mixed
double alkali adduct ions [M 2 H1Na1K]1 resulting
in additional signals at m/z 429116 and 636116. The
possibility that these fragments might be related to a
hydroxylated derivative can be excluded for two rea-
sons: first, there is no corresponding molecular ion, and
second, a hydroxylated derivative would elute before
the corresponding nonhydroxylated species, which we
indeed observed in the chromatogram.
Although conventional ESI leads to resulting spectra
containing mainly molecular ions [6, 20, 22], the op-
tional use of CID in the skimmer region provides an
important approach to structural information. The fact,
that fragmentation under the CID conditions applied
induces only a limited number of cleavage reactions
limits further structural elucidation of SDZ RAD me-
tabolites. Because the carbon chain between C(15) and
C(27) did not suffer cleavage under the chosen condi-
tions, the obtained CID spectra of the monohydroxy-
lated derivatives of SDZ RAD did not allow definite
identification of the position of hydroxylation. Addi-
tional NMR experiments as carried out by Wang et al.
for sirolimus metabolites [23] and Iwasaki et al. for
transformation products of tacrolimus [21] might en-
able definite differentiation between structural isomers.
Our investigations show, that for further ESI-MS stud-
ies on SDZ RAD metabolism, LC separation has to be
improved but not the technical parameters of mass
spectrometry. The spectra obtained were of high quality
sufficient for interpretation within the framework.
Conclusion
ESI-MS in conjunction with the CID technique is a
powerful tool for the structural elucidation of unknown
compounds such as metabolites from incubation ex-
tracts. In the case of complex mixtures, more selectivity
can be achieved by using LC separation coupled to
mass spectrometry.
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